BriaCell Therapeutics Corp. (BCTX)

BriaCell Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is August - July.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May 1, 2026	Jul 31, 2025	Jul 31, 2024	Jul 31, 2023	Jul 31, 2022	Jul 31, 2021
Market Cap	30	19	19	140	128	98
Market Cap Growth	82.47%	1.06%	-86.55%	9.34%	30.61%	1321.88%
Enterprise Value	-0.3	0.62	17.22	111.96	75.44	26.58
Last Close Price	4.18	10.10	154.49	1314.00	1257.76	963.00
PE Ratio	-	-0.12	-2.56	-5.11	-3.78	-1.68
PB Ratio	1.00	1.06	-5.72	-28.09	9.67	2.84
P/TBV Ratio	0.27	0.33	-7.11	-36.22	12.58	1.05
P/FCF Ratio	-	-0.49	-0.55	-4.47	-8.00	-10.14
P/OCF Ratio	-	-0.49	-0.57	-4.47	-8.00	-10.14
EV/EBITDA Ratio	-	-0.02	-0.38	-3.65	-3.85	-3.06
EV/EBIT Ratio	-	-0.02	-0.37	-3.65	-3.85	-3.05
EV/FCF Ratio	-	-0.02	-0.51	-3.57	-4.71	-2.75
Net Debt / Equity Ratio	-0.97	-1.00	0.36	5.63	-3.97	-2.07
Net Debt / EBITDA Ratio	0.78	0.48	0.03	0.91	2.69	8.23
Net Debt / FCF Ratio	0.82	0.46	0.04	0.90	3.29	7.39
Quick Ratio	10.10	5.01	0.49	14.96	43.64	102.88
Current Ratio	10.10	5.01	0.49	14.96	45.00	103.81
Return on Equity (ROE)	-191.31%	-540.66%	152.63%	-619.75%	-141.25%	-114.78%
Return on Assets (ROA)	-166.87%	-253.13%	-201.78%	-66.74%	-30.39%	-23.82%
Return on Invested Capital (ROIC)	-77732.50%	2099.63%	-4015.57%	-989.19%	-3763.04%	465.90%
Return on Capital Employed (ROCE)	-193.67%	-487.40%	-280.40%	-69.47%	-30.85%	-25.82%
Earnings Yield	-97.84%	-853.09%	-39.04%	-19.58%	-26.44%	-59.47%
FCF Yield	-102.23%	-205.12%	-180.25%	-22.38%	-12.50%	-9.86%
Buyback Yield / Dilution	-784.70%	-285.70%	-5.35%	-0.81%	-242.82%	-533.09%
Total Shareholder Return	-784.70%	-285.70%	-5.35%	-0.81%	-242.82%	-533.09%

Updated Mar 10, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q